Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial

The Lancet

Volumn 390, Issue 10105, 2017, Pages 1833-1842

  Ridker, Paul M ^a,c   MacFadyen, Jean G ^a   Thuren, Tom ^b,c   Everett, Brendan ^c   Libby, Peter ^a,c   Glynn, Robert J ^a,c   Lorenzatti, Alberto ^c   Krum, Henry ^c   Varigos, John ^c   Siostrzonek, Peter ^c   Sinnaeve, Peter ^c   Fonseca, Francisco ^c   Nicolau, Jose ^c   Gotcheva, Nina ^c   Genest, Jacques ^c   Yong, Huo ^c   Urina Triana, Miguel ^c   Milicic, Davor ^c   Cifkova, Renata ^c   Vettus, Riina ^c   Koenig, Wolfgang ^c   Anker, Stephan D ^c   Manolis, Athanasios J ^c   Wyss, Fernando ^c   Forster, Tamas ^c   Sigurdsson, Axel ^c   Pais, Prem ^c   Fucili, Alessandro ^c   Ogawa, Hisao ^c   Shimokawa, Hiroaki ^c   Veze, Irina ^c   Petrauskiene, Birute ^c   Salvador, Leon ^c   Kastelein, John ^c   Cornel, Jan Hein ^c   Klemsdal, Tor Ole ^c   Medina, Felix ^c   Budaj, Andrzej ^c   Vida Simiti, Luminita ^c   Kobalava, Zhanna ^c   Otasevic, Petar ^c   Pella, Daniel ^c   Lainscak, Mitja ^c   Seung, Ki Bae ^c   Commerford, Patrick ^c   Dellborg, Mikael ^c   Donath, Marc ^c   Hwang, Juey Jen ^c   Kultursay, Hakan ^c   Flather, Marcus ^c   Ballantyne, Christie ^c   Bilazarian, Seth ^c   Chang, William ^c   East, Cara ^c   Forgosh, Les ^c   Harris, Barry ^c   Ligueros, Monica ^c   Bohula, Erin ^c   Charmarthi, Bindu ^c   Cheng, Susan ^c   Chou, Sherry ^c   Danik, Jacqueline ^c   McMahon, Graham ^c   Maron, Bradley ^c   Ning, MingMing ^c   Olenchock, Benjamin ^c   Pande, Reena ^c   Perlstein, Todd ^c   Pradhan, Aruna ^c   Rost, Natalia ^c   Singhal, Aneesh ^c   Taqueti, Viviany ^c   Wei, Nancy ^c   Burris, Howard ^c   Cioffi, Angela ^c   Dalseg, Anne Marie ^c   Ghosh, Nilanjan ^c   Gralow, Julie ^c   Mayer, Tina ^c   Rugo, Hope ^c   Fowler, Vance ^c   Limaye, Ajit P ^c   Cosgrove, Sara ^c   Levine, Donald ^c   Lopes, Renato ^c   Scott, John ^c   Hilkert, Robert ^c   Tamesby, Georgia ^c   Mickel, Carolyn ^c   Manning, Brian ^c   Woelcke, Julian ^c   Tan, Monique ^c   Manfreda, Sheryl ^c   Ponce, Tom ^c   Kam, Jane ^c   Saini, Ravinder ^c   Banker, Kehur ^c   Salko, Thomas ^c   Nandy, Panjat ^c   Tawfik, Ronda ^c   O'Neil, Greg ^c   Manne, Shobha ^c   Jirvankar, Pravin ^c   Lal, Shankar ^c   Nema, Deepak ^c   Jose, Jaison ^c   Collins, Rory ^c   Bailey, Kent ^c   Blumenthal, Roger ^c   Colhoun, Helen ^c   Gersh, Bernard ^c   more..

^a HARVARD MEDICAL SCHOOL   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CANAKINUMAB; INTERLEUKIN 1BETA; INTERLEUKIN 6; ANTIINFLAMMATORY AGENT; MONOCLONAL ANTIBODY;

ADULT; AGED; ALL CAUSE MORTALITY; ARTHRITIS; ARTICLE; ATHEROSCLEROSIS; BASAL CELL CARCINOMA; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER MORTALITY; CANCER RISK; CARDIOVASCULAR MORTALITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; FEMALE; FOLLOW UP; GOUT; HEART INFARCTION; HUMAN; INFECTION; INTENTION TO TREAT ANALYSIS; LUNG ADENOCARCINOMA; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; OSTEOARTHRITIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN SYNTHESIS INHIBITION; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; SEPSIS; SMALL CELL LUNG CANCER; SQUAMOUS CELL LUNG CARCINOMA; THROMBOCYTOPENIA; ANTAGONISTS AND INHIBITORS; BLOOD; CELL TRANSFORMATION; IMMUNOLOGY; INCIDENCE; LUNG TUMOR; MIDDLE AGED; MORTALITY; SMOKING;

AGED; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; ATHEROSCLEROSIS; C-REACTIVE PROTEIN; CELL TRANSFORMATION, NEOPLASTIC; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; INCIDENCE; INTERLEUKIN-1BETA; INTERLEUKIN-6; LUNG NEOPLASMS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; NEUTROPENIA; SEPSIS; SMOKING; THROMBOCYTOPENIA;

EID: 85028364235     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(17)32247-X     Document Type: Article

References (33)

1. Coussens, LM, Werb, Z, Inflammation and cancer. Nature 420 (2002), 860–867.
2. Grivennikov, SI, Greten, FR, Karin, M, Immunity, inflammation, and cancer. Cell 140 (2010), 883–899.
3. Apte, RN, Dotan, S, Elkabets, M, et al. The involvement of IL-1 in tumorigenesis, tumor invasiveness, metastasis and tumor-host interactions. Cancer Metastasis Rev 25 (2006), 387–408.
4. Porta, C, Larghi, P, Rimoldi, M, et al. Cellular and molecular pathways linking inflammation and cancer. Immunobiology 214 (2009), 761–777.
5. Balkwill, FR, Mantovani, A, Cancer-related inflammation: common themes and therapeutic opportunities. Semin Cancer Biol 22 (2012), 33–40.
6. O'Callaghan, DS, O'Donnell, D, O'Connell, F, O'Byrne, KJ, The role of inflammation in the pathogenesis of non-small cell lung cancer. J Thorac Oncol 5 (2010), 2024–2036.
7. Lee, JM, Yanagawa, J, Peebles, KA, Sharma, S, Mao, JT, Dubinett, SM, Inflammation in lung carcinogenesis: new targets for lung cancer chemoprevention and treatment. Crit Rev Oncol Hematol 66 (2008), 208–217.
8. Dostert, C, Petrilli, V, Van Bruggen, R, Steele, C, Mossman, BT, Tschopp, J, Innate immune activation through Nalp3 inflammasome sensing of asbestos and silica. Science 320 (2008), 674–677.
9. Gasse, P, Mary, C, Guenon, I, et al. IL-1R1/MyD88 signaling and the inflammasome are essential in pulmonary inflammation and fibrosis in mice. J Clin Invest 117 (2007), 3786–3799.
10. Voronov, E, Shouval, DS, et al. IL-1 is required for tumor invasiveness and angiogenesis. Proc Natl Acad Sci USA 100 (2003), 2645–2650.
11. Dinarello, CA, Simon, A, van der Meer, JW, Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases. Nat Rev Drug Discov 11 (2012), 633–652.
12. Dinarello, CA, Why not treat human cancer with interleukin-1 blockade?. Cancer Metastasis Rev 29 (2010), 317–329.
13. Apte, RN, Voronov, E, Is interleukin-1 a good or bad “guy” in tumor immunobiology and immunotherapy?. Immunol Rev 222 (2008), 222–241.
14. Lewis, AM, Varghese, S, Xu, H, Alexander, HR, Interleukin-1 and cancer progression: the emerging role of interleukin-1 receptor antagonist as a novel therapeutic agent in cancer treatment. J Transl Med, 4, 2006, 48.
15. Ridker, PM, Thuren, T, Zalewski, A, Libby, P, Interleukin-1beta inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS). Am Heart J 162 (2011), 597–605.
16. Ridker, PM, Howard, CP, Walter, V, et al. Effects of interleukin-1beta inhibition with canakinumab on hemoglobin A1c, lipids, C-reactive protein, interleukin-6, and fibrinogen: a phase IIb randomized, placebo-controlled trial. Circulation 126 (2012), 2739–2748.
17. Ridker PM, Everett B, Thuren T, et al, on behalf of the CANTOS Trial Group. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med (in press).
18. Siemes, C, Visser, LE, Coebergh, JW, et al. C-reactive protein levels, variation in the C-reactive protein gene, and cancer risk: the Rotterdam study. J Clin Oncol 24 (2006), 5216–5222.
19. Allin, KH, Bojesen, SE, Nordestgaard, BG, Baseline C-reactive protein is associated with incident cancer and survival in patients with cancer. J Clin Oncol 27 (2009), 2217–2224.
20. Chaturvedi, AK, Caporaso, NE, Katki, HA, et al. C-reactive protein and risk of lung cancer. J Clin Oncol 28 (2010), 2719–2726.
21. Carmi, Y, Rinott, G, Dotan, S, et al. Microenvironmental-derived IL-1 and IL-17 interact in the control of lung metastasis. J Immunol 186 (2011), 3462–3471.
22. Balkwill, F, Mantovani, A, Inflammation and cancer: back to Virchow?. Lancet 357 (2001), 539–545.
23. Cuzick, J, Otto, F, Baron, JA, et al. Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement. Lancet Oncol 10 (2009), 501–507.
24. Rothwell, PM, Fowkes, FGR, Belch, JFF, Ogawa, H, Warlow, CP, Meade, TW, Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet 377 (2011), 31–41.
25. Bhat, IA, Naykoo, NA, Qasim, I, et al. Association of interleukin 1 beta (IL-1beta) polymorphism with mRNA expression and risk of non small cell lung cancer. Meta Gene 2 (2014), 123–133.
26. Lind, H, Zienolddiny, S, Ryberg, D, Skaug, V, Phillips, DH, Haugen, A, Interleukin 1 receptor antagonist gene polymorphism and risk of lung cancer: a possible interaction with polymorphisms in the interleukin 1 beta gene. Lung Cancer 50 (2005), 285–290.
27. Zienolddiny, S, Ryberg, D, Maggini, V, Skaug, V, Canzian, F, Haugen, A, Polymorphisms of the interleukin-1 beta gene are associated with increased risk of non-small cell lung cancer. Int J Cancer 109 (2004), 353–356.
28. Hu, Z, Shao, M, Chen, Y, et al. Allele 2 of the interleukin-1 receptor antagonist gene (IL1RN*2) is associated with a decreased risk of primary lung cancer. Cancer Lett 236 (2006), 269–275.
29. Calle, EE, Kaaks, R, Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer 4 (2004), 579–591.
30. Lust, JA, Lacy, MQ, Zeldenrust, SR, et al. Induction of a chronic disease state in patients with smoldering or indolent multiple myeloma by targeting interleukin 1α-induced interleukin 6 production and the myeloma proliferative component. Mayo Clin Proc 84 (2009), 114–122.
31. Hong, DS, Hui, D, Bruera, E, et al. MABp1, a first-in-class true human antibody targeting interleukin-1α in refractory cancers: an open-label, phase 1 dose-escalation and expansion study. Lancet Oncol 15 (2014), 656–666.
32. The Interleukin-6 Receptor Mendelian Randomisation Analysis (IL6R MR) Consortium. The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis. Lancet 379 (2012), 1214–1224.
33. IL6R Genetics Consortium Emerging Risk Factors Collaboration. Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies. Lancet 379 (2012), 1205–1213.